News
Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap ...
Ozempic maker Novo Nordisk confirmed Tuesday its popular weight loss drug Wegovy had been approved for sale in China, a key victory for the Danish firm that opens the door to an enormous market ...
The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...
Hims & Hers Health stock plunged after Novo Nordisk (NYSE: NVO) cut ties over concerns about its handling of Wegovy ...
Blockbuster obesity drug Wegovy has been approved in China, opening the door for maker Novo Nordisk NOVO.B1.91%increase; green up pointing triangle to begin selling it in the world’s second ...
of Danish drugmaker Novo Nordisk rose Tuesday after the company announced that its popular weight-loss drug Wegovy has been approved to start being sold in China. Ozempic, another drug with the ...
The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...
Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management, opening up the blockbuster drug for sale in the world's second largest ...
Zacks Investment Research on MSN5d
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results